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Abstract
Many researchers working in the field of human genetics in the United States have been
caught between two seemingly competing messages with regard to racial categories and
genetic difference. As the human genome was mapped in 2000, Francis Collins, the head of
the publicly funded project, together with his privately funded rival, announced that humans
were 99.9 percent the same at the level of their genome. That same year, the National Insti-
tutes of Health (NIH) began a research program on pharmacogenetics that would exploit the
.01 percent of human genetic difference, increasingly understood in racial terms, to advance
the field of pharmacy. First, this article addresses Collins’ summary of what he called the
‘vigorous debate’ on the relationship between race and genetics in the open-access special
issue of Nature Genetics entitled ‘Genetics for the Human Race’ in 2004. Second, it examines
the most vexed (if not always openly stated) issue at stake in the debate: that many geneticists
today work with the assumption that human biology differs by race as it is conceived through
American census categories. It then presents interviews with researchers in two collaborating
US laboratories who collect and organize DNA by American notions of ‘race/ethnicity’ and
assume that US race categories of classification largely traduce human biogenetic difference.
It concludes that race is a practical and conceptual tool whose utility and function is often
taken for granted rather than rigorously assessed and that ‘rational medicine’ cannot precede
a rational approach to addressing the nature of racial disparities, difference and inequality in
health and society more broadly.
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All interpretation of meaning, like all scientific observation, strives for clarity and ver-
ifiable accuracy of insight and comprehension (Evidenz). The basis for certainty in
understanding can be either rational, which can be further subdivided into logical
and mathematical, or it can be of an emotionally empathetic or artistically apprecia-
tive quality (Weber, 1964/1947: 90).
Duana Fullwiley is an anthropologist of science and medicine concerned with how personal identity, health status
and molecular genetics findings increasingly intersect. She has done ethnographic fieldwork in the US, France and
Senegal, West Africa on locally varied versions of sickle cell science and medical care. She is also engaged in field-
work on emergent genetic technologies of race and ancestry testing for pharmaceutical and identity purposes.
Fullwiley is currently a Robert Wood Johnson Health and Society Scholar at the Harvard School of Public Health.
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American National Institutes of Health (NIH) articulated a new goal to ‘rationalize’
medicine.
1 Like most accounts of rationalization, the underlying logic of the NIH’s new
effort was about assuring better practices and securing higher efficiency in drug prescrip-
tion. The PGRN scientific teams have spent the past six years looking for clues to fit
humans’ varied, yet specific, genetic profiles to the right pharmaceuticals, and vice versa.
The rationale is a move away from what has been called the ‘one-size fits all’ approach to
drug prescription (National Institutes of General Medical Sciences, 2000). With this trend
in science, came the idea that a focus upon human genetic difference, which in the US has
often translated to racial group distinction, was the right conceptual tool to bring together
genetics and pharmacology. This emphasis on exploiting such difference was posited in
the very same year that the leaders of both public and private genome mapping teams,
Francis Collins and J. Craig Venter, publicly proclaimed that ‘we are all 99.9
percent genetically the same regardless of race’ (White House, Office of the Press
Secretary, 2000).
Four years after Collins’ and Venter’s White House announcement, a conference was
convened at the historically black Howard University (Collins, 2004: S14). In the special
supplement of Nature Genetics titled Genetics for the Human Race that published
papers from this conference, Francis Collins, as the head of the National Genome
Research Institute, revisited certain aspects of the debate: on the one hand, there were
scientists who maintained that ‘self-identified race or ethnicity is a useful proxy for other
correlated nongenetic variables’, while, on the other hand, detractors were said to ‘argue
that race and ethnicity are such flawed concepts that the persistent use of such descrip-
tors prolongs the delay in seeking real causes and lends more scientific validity to the
race–health connection than it deserves’ (Collins, 2004: S14). He continued: ‘After
reviewing these arguments and listening to the debate ... one could conclude that
both points are correct’ (2004: S14). Aware that the debate itself had rekindled the
idea that human biology might differ by race, and that the discussion cannot move on
until we define what is meant by race and its connection with biology, Collins once
more addressed the issue with strategic nuance. After positing that ‘ancestral origins’,
in many cases, ‘may have a correlation’ to ‘self-identified race’, however ‘imprecise’,
he added: ‘it is not strictly true that race or ethnicity has no biological connection’
(2004: S13, emphasis added).
Collins ends his article by setting out seven key points to indicate ‘what additional
research is needed’ (2004: S14), ranging from the need to move beyond ‘weak surrogate
relationships ... to get to the root causes of health and disease’ to a call for more
research into environmental factors, followed by a caveat that ‘if only genetic factors
are considered, [then] only genetic factors will be discovered’, to calls for ‘more anthro-
pological, sociological and psychological research into how individuals and cultures
1 The term ‘rational medicine’ is often used to describe pharmacogenetics. For more on this idea and the ‘dictate’
that race be used to guide this thinking, see Evans and Relling, where, in one of the first reviews on the issue,
they write:
... all pharmacogenetic polymorphisms studied to date differ in frequency among ethnic and racial groups. ... The
marked racial and ethnic diversity in the frequency of functional polymorphisms in drug- and xenobiotic-
metabolizing enzymes dictates that race be considered in studies aimed at discovering whether specific genotypes
or phenotypes are associated with disease risk or drug toxicity (1999: 488).
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from that specifying attention to ‘culture’, he also added that: ‘we must assess how the
scientific community uses the concepts of race and ethnicity and attempt to remedy
situations in which the use of such concepts is misleading or counterproductive’ (2004:
S15). In this article I present some such uses. Through ethnographic observation, with
affinities to that of ‘scientific observation’ described by Max Weber in the opening
epigraph, I provide excerpts of rationales from scientists on their uses of race, its ‘clarity’
and ‘accuracy’, as it functions as a ‘practical operator’ in their daily research lives
(Bourdieu, 1977: 97).
One year before the Howard conference, in 2003, I began conducting fieldwork in two
collaborating laboratories where researchers were focused on the intersection of pharmaco-
genetics and race. (They were among the first cohort granted NIH funding in the first cycle
of PRGN awards.) During my research, it became clear that the ambition to produce
rational medicine or ‘individualized medicine’ often led scientists to extrapolate from the
‘individual’ DNA differences they witnessed in the lab to the general categories of racial
grouping used in the US, with all of their complexities. In doing so, many came to believe
not simply that race should be used as ‘a useful proxy for other nongenetic variables’, but
also that human biology differed by race in a more or less consistent way. Beyond the
labs where I worked, one finds evidence of what I have called the ‘molecularization of
race’ (Fullwiley, 2007) in and alongside efforts to specifically address ‘minority health’
and in broader moves to research genetic variation between groups in the form of PGRN
supplementary grants to collect ‘diverse’ (non-white) DNA.
2 Empirically, scientists’ belief
that biology differs by race becomes clear in their daily practice of collecting and sorting
human DNA, as well as in their discovery and analysis of oftentimes very infrequent (i.e.
individual, rather than group) findings in human genetic variation as these may bear on
pharmaceutical susceptibility.
In the space permitted here, I concentrate my efforts on understanding how, despite
the rigorous naming and interpreting of genetic data through the prism of race, as well
as a belief on the part of many pharmacogenetics practitioners that human biology
corresponds to US census categories (see Fullwiley, 2007: 13–17), the concept of race
itself eludes various of my key informants working in this field.
3 How, I ask, does
this happen?
The answers are not simple. New reports regularly carry stories of findings from associa-
tion studies indicating that US populations divided along common socially accepted racial
lines are afflicted by differing rates of disease and death. The conclusion drawn by many
scientists and lay readers is that race must be biological. Many of those both in the life
and in the social sciences feel that further investigation is required into the environmental
factors that may impress upon genetic expression. These researchers suspect that genes often
get associated with ‘outcomes’ which are in fact the biological and bodily consequences of
living one’s life as a racialized subject in North America (Braun, 2002; Cooper et al.,
2 See the goals and recent grants of the ‘Ethics and Communities’ arm of the program at http://www.nigms.nih.gov/
pharmacogenetics/prnsupp_abstracts.html
3 American census category definitions of race are often used in genetics studies in spite of thoughtful editorials that
detail the pitfalls of this practice (see Nature Genetics, 2000).
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complexities, many others feel justified in analyzing DNA taken from peoples who identify,
or are identified, as belonging to a particular racial group for the purposes of scientific stu-
dies (Burchard et al., 2003; Risch et al., 2002). The dual message from some of America’s
leading genome researchers—that race matters in genetics, and that we should move beyond
race as a surrogate—leaves most of the scientists with whom I conducted fieldwork
confused about what they are finding, how it should be interpreted and to whom. In this
article I suggest that scientists often get stuck between two, if not more, discourses, as
they are convinced by the many studies that tease out racial difference, yet they know, intel-
lectually, that there are myriad problems to racial generalizations derived from findings such
as their own. I have mostly worked with researchers who deal with very rare mutations that
may or may not be unevenly distributed between the US racialized groups that these
researchers have decided to study through convenience and geographical availability
(due to the fact that recruited subjects live in the San Franscisco Bay area, where these
labs are located, in large numbers).
Daily dynamics
In what follows, I draw on interviews with two teams of pharmacogenetic scientists at the
end of a six-month fieldwork stay in two labs when trust and, in many instances, degrees
of friendship had been established. The reader may wonder about ethnographic power
dynamics when such charged issues are at stake, about racial tensions or affinities shared
between the anthropologist of race-use in science and her race-using ‘subjects’. Many of
my interlocutors self-identified as ‘bi-racial’, and understood me to be ‘bi-racial’, while
they were also oftentimes ‘bi-cultural’. Several who self-identified as ‘white/Caucasian’
were involved in ‘bi-racial’ relationships and, during my fieldwork, one such self-identifier
had his first child, who was bi-racial. Yet, they possessed very recently ‘mixed heritage’,
unlike my own, which is African-American and English-Irish-American within a family
that has been in the US for at least five generations (according to my Mormon relatives).
Most researchers with bi-racial and/or bi-cultural experiences had one parent who had
arrived as a first-generation immigrant, or had themselves recently come to the US. Such
was the case for several scientists from Asia, South Asia and Europe. Four of the world’s
continents were represented by scientists in the two labs. As we will see below, the principal
lab discussed here was interested in comparing four US racial/ethnic groups that they termed
‘African-Americans’, ‘Chinese-Americans’, ‘Caucasian-Americans’ and ‘Mexican-Americans’.
With the exception of African-American, each of these groups had ‘scientific representation’
on the two teams, or scientists who self-identified, at least in part, with the ‘origins’ rooted
in these hyphenated terms. Several African-American temporary recruiters, or students
visiting through mentorship programs, did pass through for short stays periodically. No
Africans were ever affiliated with the labs.
Manyoftheresearchersatthesetwositeswereofroughlymyageatthetime(late20searly
30s), although some were considerably older. In the practice of participant observation, I
occupied a position known to my informants as ‘shadowing’, a process whereby they would
inform me of scientific issues and help me to understand their projects and various technolo-
gies. They were also free to ask me questions, and often posed queries regarding whether or
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sence as ethnographer and observer did not affect all in the same way: one researcher was ner-
vousandwonderediftheywerebeing‘audited’.Otherssworemetosecrecyabouttheirpapers
in progress, worried that I might accidentally lead to them being ‘scooped’ (I indeed promised
them confidentiality, as I worked with other labs). Yet most entered into conversations, daily
work and relationships with me with relative ease. People understood that they were free to
talk with me as they liked, or not. The majority chose to let me shadow them from time to
time, graciously answered my various queries, and seemed to enjoy sharing aspects of their
work that were either frustrating, exciting, or both. One graduate student confided that no
one outside of the lab had ever let him finish his project description in a casual conversa-
tion—not even his dad, and thus was ‘happy to talk’. One lead researcher who quickly
informed me that most of the variation they were finding was ‘African- American’, and that
thus‘clearlyracewasimportantforgenetics’,askedthatI‘learnandengagewithsomeoftheir
science’. Another informed me that a key African-American sociologist had criticized him
publicly, and that he simply hoped that ‘we could each keep an open mind’ about what he
called‘therealityofrace’.Hegladlyinvitedmetostudyhisownlabseparately,whichresulted
in an extended stay with his group as well.
After months of witnessing the selection of human subjects, the collection of DNA
samples, the organization of those samples by race (in spaces ranging from the virtual orga-
nization of computerized databases to the placement and storage of DNA in sub-20 or 80
degree freezers), I eventually asked each scientist about their sorting technique of racial bin-
ning. The latter was self-evident for many, and unquestioned by most. Because the centrality
of race was obvious—a visible yet invisible technology that infused all stages of the
research—I came to wonder, and finally asked my interlocutors: ‘How do you define
race?’ Like Collins, I had assumed a certain ‘clarity’. In so doing, I committed an error,
for practical categories are not always obvious and the ‘essential characteristic of practice’
may be ‘precisely the fact that excludes such questions’ (Bourdieu, 1977: 106). Most of
my informants drew a blank at the question, leading to a pause in the interview that lasted
anywhere from 5 to 30 seconds before they then offered responses that were often unsure.
4
The pause was, in some cases, the product of a desire to be cautious around such a conten-
tious issue. Yet for the most part, it was simply due to confusion about what race is. When
probed about its relationship to genetics, and to their projects in particular, their usual intel-
lectual rigor was replaced with nervous laughter and, in some cases, embarrassment. As one
exclaimed, they simply ‘did not understand what race is!’
Race and nominalism
Race is a thing of our world like no other. Americans in general often use the word without
much reflection. It might indeed occupy a tiny portion of what philosopher Martin Heidegger
amorphously termed ‘the background’, that which just is and does not warrant our reflec-
tion until its unity ‘breaks down’. Even when the breakdown of race occurs in many
areas of American social life, it is often reconstructed and made ‘whole’ again. One recent
4 All interviews were conducted on a Sony digital minidisk recording device. The timing of these pauses is based on
the digital timing mechanism inscribed in each recording.
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report themselves as ‘mixed race’. Many African-Americans with mixed ancestry did not
choose this option, but simply marked the category that best represented descriptions that
they had been raised to understand themselves ‘to be’ in North America—that is ‘mono-
racially’ black (Lee and Bean, 2004: 233). The decision to mark oneself or not mark oneself
as mixed-race differed according to where respondents lived—notably between those who
lived in the deep South and those who lived in the ten states where 64 percent of all multi-
racial identification took place (New York and California among them, as well as Hawaii).
In general, those in cosmopolitan centers, with high rates of immigration, diversity, and
more demonstrated tolerance of others, were more likely to report racial mixing (Lee and
Bean, 2004: 235). Perhaps more telling, when Americans acted on the liberty of marking
more than one category, the National Center for Health Statistics created a formula that,
in effect, ‘reallocated’ the multiracial population back into a single race group (Wellner,
2003: 2). This move, and the technology permitting it, was presented as an aid to market
researchers who were vexed by the 2000 census data, which complicated their traditional
formulas of ‘niche’ advertising to racial groups (Wellner, 2003: 2).
There is a long debate in philosophy between ‘realists’ who argue that the mind names
entities that correspond to likenesses ‘out there’ in the world, and ‘nominalists’ who, at their
most extreme, argue that all names, categories and taxonomies are imposed on the world by
the human senses. Mediating between these positions, Ian Hacking has proposed the concept
of ‘dynamic nominalism’, suggesting that ‘our practices of naming interact with the things
that we name’ (2002: 6). As sociologist Troy Duster has put it: ‘when race is used as a
stratifying practice (which can be apprehended empirically and systematically) there is often
a reciprocal interplay of biological outcomes that makes it impossible to completely
disentangle the biological from the social’ (2001: 221). Both Hacking and Duster are
concerned with the interchange ‘between what there is (and what comes into being) and
our conceptions of it’ (Hacking, 2002: 6). Race in many respects demands an analysis that
pries open this ‘looping effect of human kinds’ (Hacking, 1995) through beliefs about the
self, others and ‘the human’ more generally. To get to some of these issues, I query scientists’
views about the purity of race and their use of it to define human variation even as competing
discourses about its validity for genetics simultaneously circulate in the larger cultural field.
In the principal pharmacogenetics laboratory I draw upon here, one arc of this looping
effect was a tracking of human difference through documenting frequency differences in the
distribution of Single Nucleotide Polymorphisms, or SNPs, between groups distinguished by
common racial categories in the United States. This happened without much reflection, in
part because the lines of race were seen to be there; and, through their very social reality,
they subsumed the imprints of human population history (periods of isolation, migration
and mixing), geography, and, in some respects, the very bounds of these scientists’ own
vision. Percentages are a crucial conceptual tool for pharmacogenetics: the threshold for
defining something as a SNP is that it must occur in 1 percent of the sampled population—
that is to say, it must not be simply a variation in a single or few rare individuals. Yet, in
certain cases, frequencies of less than 1 percent were used in discussions about how best
to define human difference as it relates to pharmacogenetics. Nucleotide changes found
once (on one chromosome in one person in a defined study) are said to be ‘singletons’, those
found twice ‘doubletons’ and those three times, ‘tripletons’, etc. Such exceedingly rare
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conceptual place in the lab that often served to reify the biogenetic basis of human differ-
ence. This was, however, not solely a matter of giving salience to human particularism.
These rare findings, as will be seen in one of the interviews to follow, came to be conceived
of as important for research because they had the potential to further scientific knowledge
on drug uptake mechanisms, and could thus benefit humanity as a whole. One of the
long-standing ironies of humanist discourse has been that an orientation to human particu-
lars is justified by an appeal to universal benefit. For the science at hand, the key point is
that ‘individuals’ come to stand in for ‘populations’. And yet, of course, conceptually and
practically, individuals are not populations.
The labs
In early March 2003, I began a six-month fieldwork stay at the University of California, San
Francisco’s (UCSF) Department of Biopharmaceutical Sciences whose chair, Kathleen
Giacomini, has a four-year grant as part of the PGRN to conduct a study on the Pharmaco-
genetics of cell Membrane Transporters (or PMT).
5 Cell membrane transporters are vital to
understanding the first and last phases of drug distribution, since these are proteins that sit
on the outside or inside of cells that determine what chemical substance gets taken up, and
in what quantities (influx), and what gets expelled when necessary (efflux). Any drug to
which we are exposed—toxin or medication—must interact with transporters before it
can be metabolized by enzymes (which have been the focus of pharmacogenetics since the
1950s). The PMT project is ambitious, with over 52 transporters and their genetic variants
being characterized, tested in cell systems and, finally, investigators hope, challenged by
their drug substrates in animals or humans.
Giacomini worked with another local researcher, Esteban Gonz  a alez Burchard, to help
her collect a panel of ‘ethnically and racially’ diverse DNA donors for clinical trials. This
cohort was called SOPHIE and it consisted of ‘African-Americans’, ‘Caucasian-Americans’,
‘Mexican-Americans’ and ‘Chinese-Americans’ who would consent to be called back for
in vivo drug trials and who lived locally in northern California. Members from the Burchard
lab were responsible for recruitment. The point of recruiting individuals to participate in
SOPHIE was to overcome what PMT researchers saw as limitations in the National Insti-
tutes of General Medical Sciences’ ethnically diverse DNA panels. These are the ‘Poly-
morphism Discovery Resource Panel’ (PDR) and the Coriell Institute’s ‘Human Variation’
panels, which my informants simply referred to as ‘Coriell’.
Researchers involved in PMT are pioneers of their fields. No one has done more extens-
ive work on cell membrane transporters than Kathleen Giacomini. Her achievements have
been recognized by the International Pharmaceutical Federation (FIP) Pharmaceutical Scien-
tist of the Year award in 1999 and election to the American Association for the Advance-
ment of Science in 2001. Others at the helm of the project have received prestigious
accolades, such as membership at the Institute of Medicine, the National Academy of
5 Due to either their high profiles, or to the extreme specificity of their research, scientists’ real names are used
throughout (when they are named). Consent to do so was obtained by the author and approved through New
York University’s IRB option for attribution on the part of human subjects.
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tions in the United States where one can practice science, and its program in biopharmaceu-
tical sciences ranks as one of the best nationwide.
Definitions and Meanings
The word ‘meaning’ has many uses, many of which are more evocative than precise.
(Hacking, 1983: 75)
After only a few weeks with PMT, it became clear that the use of race was less a meaning-
laden activity than a practical tool to organize their study, and a way to drive hypotheses
about how their research findings might eventually shed light on population disease risk
and pharmacological susceptibility. Most of the variation that PMT scientists found was
what they termed ‘cosmopolitan’, i.e. it existed in all racialized groups under study. Yet
the rare protein-altering variants were largely found in specific groups and, in African-
Americans in particular. The team and their collaborators interpreted this to mean that their
findings were in keeping with much evolutionary genetics. Most working in this area believe
that genomes from African populations have the most variation as a result of the ‘Out of
Africa’ event that, for thousands of years, separated those who remained on that continent
from those who migrated to other regions of the world. For the team, this confirmed their
belief that racial groups could, and should, be talked about as biologically distinct, for
they were seeing some distinctions between the African-American samples and those labeled
‘Caucasians’. But what exactly was the racial distinction that they were using to allocate
individuals to these groups in the here and now? Several of PMT’s own top researchers
were of ‘mixed-raced’ origins, ‘Filipino and Italian’, ‘South Asian and Czechoslovakian’,
‘Mexican and French-Canadian’ and so on. In the formal interviews, when all of my ques-
tions about the definitions of transport, cellular phenotype, and pharmacological methods
and measures of uptake had been answered, I posed the obvious question about the most
basic of their scientific tools. I asked my informants to define race. The following is an
excerpt of my conversation with Kathy Giacomini on the issue.
DF: One thing that I want to ask every scientist is how he or she defines race.
KG: [laughs]
DF: And how you as a scientist explain the concept?
KG: You know—probably I haven’t given that as much thought as I should have. But
my guess would be—I mean my feeling ... of race ...[pauses for 14 seconds] ...
versus ethnicity? Or just race?
DF: Just race.
KG: [pauses for 2 seconds]
DF: As you understand it.
KG: My understanding of race is ...is ...and I don’t even know what the broad defini-
tion of race ...what the acceptable definition of race is. But my understanding of
race is that there are three major races—that there’s a Caucasian race, that that is
a race—as opposed to European, OK. And there’s an, an, an African race.
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are racial groups. Now are you going to ask me what characterizes a race? Are
you going to ask me those kinds of things [laughing shyly]?
DF: No. Just in terms of the science that you do, how do you understand it scientifically?
Does your science give you a certain vantage to understand race in a particular way?
KG: Oh, OK, yes. So there, I think there are populations that have been geographically
isolated and then formed—have their own, over the years, have their own variants,
SNPS, things that they carry within their own population because they were iso-
lated from other populations that allowed these specific isolated populations to
have their own—[well] share a common genetic make-up, but have their own par-
ticular variants that they carry within that population. So yeah, I guess I do see race
as sort of a genetic definition. I certainly saw it when I started re-sequencing these
genes. You do see very population-specific variants along with a background of
cosmopolitan variants.
I then asked about the significance of these rare variants within pharmacogenetics as a
whole. Did such SNP differences, which may be found in some members of one group,
but are not found in the majority of people from in that group, have special meaning
because they are ‘racially specific?’
DF: I know that you have discovered a lot of singletons, and those have been important
in some of your publications ...
KG: Yes.
DF: In the age of SNPs, and where everyone’s interested in SNPs, meaning that genomic
changes have to affect 1 percent of the population ...
KG: Right, 1 percent or greater.
DF: So that’s the threshold. So do your singletons get tossed out [as far as the larger scien-
tific community is concerned], or when race comes in, and the change then becomes
‘common’, or more than 1 percent for that particular race or ethnicity does that mat-
ter? Let’s say the change in question is 0.5 percent across the board or even less, but if
youjustlookatoneraceit’slarger.Doesthatsortofrescuethese rareallelesintheage
ofSNPs where there is this1 percent cut-off point? Do youfeel thatit’s worth keeping
these rare alleles, sometimes singletons, in the game even if they don’t meet that SNP
definition, across the board as 1 percent of the population?
KG: So here—let me tell you I have a couple of minds on this. First of all, a rare SNP,
and that must be an oxymoron [laughs], but a rare variant of some sort can teach
us a lot. I am very attracted to rare variants. And I’m not exactly sure why I am.
I think it’s because you can learn a lot from a rare variant. Particularly if it’s a
rare variant that hasn’t had a chance to be selected against. So it may be non-
functional, it may exist in one population, so yes I like to—I don’t want to say
rescue—I like to keep the rare variants in mind. Secondly, I do exactly what you
say. I think if it’s important in a particular ethnic group, or any particular popula-
tion, if it goes above 1 percent for that population, we should certainly consider
that because it may have a particular effect in that population alone. So I feel
very strongly that we should [do this]. But even, let’s say that it doesn’t go
above 1 percent for a specific population, that it was just found one time, on one
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mutation that was just found once, but it’s non-functional and we know it because
we tested it in the laboratory. Well, that’s probably very important for that one
individual and for his or her family. And secondly, it can tell us about mechanism
and that’s very important to me....
We have found in SOPHIE—you know when you re-sequence things, you
find things—and we found stop codons, for example, in a couple of the genes. This
meansthatthosestopcodons,especiallyiftheyareinthemiddleofthecodingregion,
aregoingtogiveusatruncatedprotein,anditwillbenon-functional.Theyarealmost
always singletons. You don’t find stop codons in big numbers. So I would love—we
know who the individuals are because they’re in SOPHIE, and I would like to study
them because I could learn something about mechanism in humans in a person that
has a non-functional allele. You know, I could learn something. So those are some
of the studies that I would like to think about designing....
And then we would learn about drug mechanism in a way that we could design
better drugs for all different people. So I am thinking about pursuing rare variants,
especially ones that are non-functional. But you’re correct. If a rare variant is found
at a certain frequency only in a certain population, I certainly wouldn’t ignore it.
Later in the interview I asked her about debates in scientific circles on the validity of race
based on clustering studies. This excerpt shows Giacomini’s ethics, and her clear concern
not to do harm by using race. It also shows her belief that science and truth will eventually
settle these dilemmas.
DF: Do you have any feeling about these genetic studies that say that we shouldn’t look
at race and that we should just allow people to cluster into groups?
KG: Oh. Those are interesting. So, I’m of two minds here. One mind I’m of is the—the
idea that race can be used to hurt people in some way bothers me. And some way,
deep down, I don’t want anything I do to ever hurt a group. Now that would be—I
don’t know, that would be bad. So part of me feels that if you could cluster in some
way it might be fine. You’d get rid of maybe having to hurt a group, by saying ‘Oh
you have this weird transporter’. I can’t imagine how that could hurt, but let’s say
you find something like that. So, yes, clustering seems OK [hesitates] ...to me. But
at the same time though, I feel like people do have racial groups and they’re proud
of it, and so they don’t even mind knowing about their variants and all of that....If
it were me, I would just want to know what my genes are period. So clustering may
help, and you read the debates, but I also don’t see anything wrong with finding the
variants in a particular ethnic group.
DF: You just have this background notion that things have been used to discriminate
against a group perhaps?
KG: Yes. You know it’s happened and you just don’t want it to happen. It concerns you,
but at the same time you feel that the optimistic view is that we do get over that and
that it ultimately will be OK.
The next excerpt comes from a postdoctoral researcher (PD) on PMT, a former graduate
student of Giacomini, who is also her closest partner on the project in terms of thinking
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several of PMT’s more comprehensive scientific journal articles.
DF: How would you define race?
PD: That’s a good question. I mean I—from my limited knowledge—and you know I’m
still learning so much about population genetics and how variation differs between
groups—but I do feel as though there are ethnic-specific SNPs. Because it seems as
though people—when people do these large-scale genomic screens, they see these
frequencies in the groups. One SNP will only pop up in one group, and another
SNP will pop up only in another group. So I do think that there’s some genetic basis
for ethnicity or race. In terms of defining a given race based on SNPs or genetic var-
iation, I don’t think we know enough yet to do that. But from what I’ve seen, I do
think that there are genetic differences, or more global genetic differences
between—and maybe it’s just sub-populations. I don’t know—I don’t really know
what defines a race or an ethnicity, and I get confused between ‘What is a race?’
and ‘What is an ethnicity?’ So ...
DF: So you’re going on what you’ve seen. You’ve seen SNPs appear in what have been
defined as different groups?
PD: Yeah. That’s what people report....I don’t know because I don’t know how they
are defining their races and ethnicities, but I do think that it’s not just chance.
...
DF: Before you got into SNP mapping, how would you have defined race?
PD: I think before I got into all of this, I would have thought, ‘Oh, where are your par-
ents from?’ And you know, my dad came from India. I actually grew up in a very
mixed background. My dad grew up in India until he was 25, and my mom is
part Czechoslovakian, so I’m of very mixed descent. So, if someone had two parents
and they were second generation, and the parents came from China, I would say oh,
they are Chinese. I mean that was my simple kind of definition of somebody’s race
or descent. But I think of it much differently now ...
DF: As a mixed person of Czechoslovakian, Indian ...
PD: And everything else! [laughs]
DF: Do you feel that the racial categories that we use, for example in the United States,
Black, White, Asian and Hispanic, etc. are too simplistic? Would you expand these
if you could?
PD: It always—as a child it always bothered me. I hated it on tests—you know, when
you took your SAT test, or when you apply for college, they ask you to check off
this box: Are you Asian, Caucasian, African-American or Other? You know, and
I didn’t feel like putting Other. You know, because Other just seems like, ‘Gosh,
I don’t belong to anything.’ It kind of makes you feel—I just thought it was weird.
I never liked the fact—no. I didn’t like the fact that you had to define yourself as
one race.... So I guess it depends on the situation. I guess in social-type things, I
don’t even want to have to think about it, if that makes any sense?... So, I have
two extremes: when I’m doing my genetic type of research, I want things very
well defined, and in a social setting I don’t even want to think about it. I don’t
know if that makes any sense? [laughs]
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facility who is responsible for the actual genotyping of PMT’s Coreill and now SOPHIE
DNA for transporter genes.
DF: One thing I’m asking every scientist, and this comes out of the debates in Nature
Genetics and other journals, is about the use of race in science and medicine. First,
how would you define race?
T: Oh geez! Touchy subject. How would I define race? Um. [pauses for 9 seconds]. I
think that—my preference would be to define race genetically. In such a way that
there are certain groups of people that share genetic markers—a set of common
genetic markers that is different from the set of genetic markers shared by a different
group. One of the difficulties that you run into when you define race is that the spe-
cies is able to have interrelationships, right? And how do you define race as a percen-
tage of ancestry?...We can produce mixed-race children. So I don’t know. I leave it
up to the sociologists I guess to define race....[laughs]
DF: So the mixed-raced children would not fit your original definition of race based on
genetic markers that are only found in one group, but not another?
T: Right.
DF: So then, scientifically, how do you keep race in the running? How do you think
about race scientifically, so that you can define it as a scientific concept?
T: Um ...I try to avoid it! [laughs] ...So, one thing you learn about being a biologist is
that you can make assumptions. You can make generalizations and they’re not going
to be true in every case. And, you know, that’s what race is. It’s a generalization. You
look at a person, or you do a genetic profile, and you say this person has a genetic
profile of a Caucasian, or this person has a genetic profile of an African-American,
but for all you know that may not be the case, and so you can only judge race to a
certain degree of confidence. Um, does that make sense?
The next excerpt comes from a postdoctoral fellow (PD) in the Burchard lab who had
recently arrived in the US from South Asia. During the first three months of her stay, she
quickly learned to use six statistical computational programs to sort DNA polymorphisms
and sieve through them for heredity patterns. On most days, in this second lab, the research-
ers were interested in Puerto Rican and Mexican asthma genetics. Yet they were trying to
understand asthma prevalence in these two groups, in part, through DNA markers found
at disproportionate rates in select ‘European’, ‘African’, and ‘Native American’ populations.
Through a process termed ‘admixture’, these latter groups were thought to ‘comprise’
the biological underpinnings of what these researchers called ‘new world’ Latino genetic
difference. After a very short training period, this postdoc was soon presenting racialized
results at lab meetings and debating which techniques and statistical measures should be
used to corroborate their findings. She eventually first-authored two important papers
wherein the lab reported their findings on race as it linked to various asthma SNPs in Puerto
Ricans and Mexicans. In our interview, she is initially quite certain that race should be used
as a practical tool for locating genes in bodies that may not possess the same percentages of
ancestry from Europe, Native America and Africa. It becomes clear that she thinks of race
somewhat like caste, which in her home country tracks with disease prevalence. Later in
the interview, however, she sees race somewhat differently when she attempts to define it.
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difference, requires more thought on her part.
DF: One of my research questions is how race is used in science....So my question to
you is, how would you define race?
PD: [pauses for 7 seconds] ...I, I, I haven’t thought about it—like in detail. There are a
lot of definitions people use. But, but, after reading all of the [debates] in the litera-
ture—I’m like—the people who say that you shouldn’t study race, and all of that,
I’m against that. Maybe studying race can give you a lot, a lot of insight. So all these
complex disorders [like asthma], why not compare different races with different
prevalences of diseases and comparing them might give you some clue that they
are different—at like, at say, at these chromosomal positions—why not study
them, right, just compare? Do this practical thing, just compare and that can give
you some clue that can narrow down your search for genes for asthma. Why not
use it instead of making—uhm, like—well, I agree that we should be very careful
when reporting all of these kinds of results, but, but then—not studying them?
Not using the information that is there? Just seeing it—in India, different castes
have different rates of diabetes, you are seeing it, why not use it, right?
DF: So, OK, you have caste in India, then within the United States [in your study] you
have Hispanics, and you have divided them up into Mexicans and Puerto Ricans.
So, you’re saying that we shouldn’t ignore race, but what is race?
PD: Uhm, so [pauses for 6 seconds] ... so usually I think the race thing people use is
[for] people who speak the same language and [have] the same social background,
...[hesitates] I think. But, then—then the thing is when you divide Mexicans and
Puerto Ricans—Mexicans and Puerto Ricans have all the same—they speak the
same language and they have almost the same social set-up, so they’re the same,
so—but then Mexicans and Puerto Ricans have very different, say asthma, they’re
very different, right? So.
DF: So, it couldn’t just be language and social background.
PD: Yeah.
DF: So, if you were to make a definition, what would you say?
PD: Race....[pause for 18 seconds] ...What would I say? [laughs slightly] ...[pauses
for 20 seconds] ...I think I need to think more about it, so.
One last excerpt from the lab head himself, Esteban Gonz  a ales Burchard, is instructive as
it contrasts with those presented thus far. For Burchard, there is no pause. The moment of
reflection in the other cases is here replaced with considerable certainty about the nature of
human race typology. Burchard’s conviction was common among my informants, but his
was clarity rare. In this interview with Burchard, we see the many themes at stake in the
debates brought together.
DF: How do you define race as a scientific concept?...That’s [part of] the debate, right,
that it is or it’s not scientific?
EB: Well, race is usually thought of in US Census terms. There are five major racial cate-
gories: African, Caucasian, Native American, Pacific Islanders and Asians. If you
don’t like the term ‘race,’ you can use ‘geographically defined groups’, as they did
R A C E A N D G E N E T I C S j
j233in the Noah Rosenberg paper. But those are just surrogates for ‘race’. If everyone
comes from the African continent, that means that they’re African, or thought of
as black in today’s terminology [pauses to think about this].
Although there are the vast majority of genetic similarities between populations,
more similarities between groups, there is still a sizeable percentage of the genome,
7 percent, that separates population groups, African from Caucasian, Asians and so
forth. And when you talk about the human genome, 7 percent is a substantial
amount of the entire genome. So, to get back to your question ...a race is a defined
set of individuals that have genetic similarity. However, race is not purely biological
like gender is—X or Y chromosome. Race has a biological component that is largely
shaped by environmental factors, sociologic factors, geographic factors—mountains,
large oceans separating populations—and those aren’t biologic in nature, but
because they are affecting a biologic process, they are of biologic importance. That’s
where the debate is, really lies, there is a sociologic component to race, but it is not
without a biologic basis.
For Burchard, the social sphere has a role to play, but the census office has race right
when the small percentage of the genome that differentiates us by continental origin is the
question. He sees the ‘biologic’ component of race as conditioned by geography and human
history, but, for him, ‘race’ as ‘a defined set of individuals that have genetic similarity’ trans-
lates to five human types. These are surely affected by the ‘sociologic’ (unlike gender for
him) but their biological ‘similarity’,’’ within the ‘7 percent’, proves ‘substantial’.
Conclusion
Pharmacogeneticsis,bydefinition,concernedwithhumandifferences,withdifferentialdistri-
bution of allelic frequencies, and considers these to have arisen over time from human beings’
interactionwith,andadaptationto, xenobioticsencounteredintheformofplants, foods,tox-
ins and the rest. It is not hard to imagine how such genomic diversity evolved, and why, as one
of the researchers cited above puts it, ‘ethnic-specific’ SNPs ‘pop up in one group, but not in
others’. The intellectual leap that takes each researcher from this particular notion of specifi-
city totheidea thatraceisthe right conceptualtooltoaccountforsuch differences ismore dif-
ficult to explain. Recall that these are reputable scientists who are familiar with the debates
and who still pursue their research with a certain conviction, full of good intentions.
With the completion of the draft of the human genome in the summer of 2000, many
people were hopeful when leading scientists also announced that race had no
genetic basis. Some imagined such statements would lead us into a new humanism in the
twenty-first century. That same year British sociologist, and postcolonial theorist, Paul
Gilroy could write:
[I] t is difficult to resist the conclusion that the biotechnological revolution demands a
change in our understanding of ‘race’ ...and human specificity. In other words it asks
that we reconceptualize our relationship to ourselves, our species, our nature and the
idea of life. We need to ask, for example, whether there should be any place in this
new paradigm of life for the idea of specifically racial differences. (2000: 20)
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and ideals that the public projected onto the Human Genome Project, with which certain
hopeful scientists ran, included ‘post-anthropological’ conceptions of humans (Gilroy,
2002: 15) as something other than ‘racial’ beings, which clustering studies might circum-
navigate (Wilson et al., 2001).
Despite the range of possibilities for race thinking presented by the completion of the
sequencing of the human genome, the deployment of race within genomic science has
most recently become a platform on which minorities themselves have come to demand
that their health be addressed by the genetic revolution. We can see this, for example, in
actions from the Association of Black Cardiologists championing BiDil as the first race-
specific heart-failure medication (Kahn, 2003: 475), and in the Howard University database
project calling for ‘African-American’ genome research (Kaiser, 2003: 1485). Genetics,
along with market notions of tailored medicine and (health) advocacy, has indeed entered
us into a new ‘humanism’ in the United States, but it is one that needs—in fact,
demands—that attention be paid to the materiality of human differences made visible by
medical genetic technology in order to somehow ‘equalize’ life chances. Equality, despite
genetic distinction, is its proclaimed goal. Inherently, this constellation of promised parity
(largely reliant on difference) raises both the specter of new forms of biological racism
and an ethical obligation to focus on those in our society who, as groups, are counted as
the most ill (who are also, not so coincidentally, those who have historically been the objects
of biological and other types of racism). Our current molecular-based humanism demands
that both social and life scientists begin to define the parameters of race, and to seriously
query its relationship to biology, culture, language, power and health. None of these cate-
gories can provide a complete account, none is reducible to the others.
More precisely tailored drug molecules may be in the pipeline, but we must pause to
consider whether or not the molecularization of race—marking DNA as raced from the
time it is extracted to the time that it appears in journal articles—is truly the best ‘pathway’
to attaining ‘rational’ and ‘individualized’ medicine. What kind of rationality is in question
here? As Weber noted, different forms of rationality can underpin social actions. For this
reason he made a distinction between rationality that was ‘technocratic/pragmatic’ versus
‘affect-based’, as well as rationality that was ‘traditional’ versus ‘value-laden, when evaluat-
ing how humans determine ‘certainty in understanding’ (Weber, 1947/1964: 90). In the case
of the use of race in pharmacogenetics, all four rationalities are in play. The accounts given
by those who I interviewed show clearly that the technocratic/pragmatic rationality so cen-
tral to the work of research operates within a value-laden, affect-based form of rationality.
We can even find traces of traditional forms, as racial taxonomies here are undergirded by
considerations other than science. Most of my interlocutors were unsure of the meanings of
the race categories that they used, yet they continue to assert that there is a biological basis
to them, which they will soon corroborate once they have done comparative studies in the
human groups defined by them. That this system reaffirms itself remains unproblematic
for many practitioners of this rational medicine.
A last lesson from Weber may be warranted in closing. One of the dangers of capitalism
is that rationalization, paradoxically, often ceases to reflect on itself, and hence behaves in
ways that undermines its goals. This is what Weber termed the irrationality of rationaliza-
tion (1947: 92). In examining rationales to develop pharmacogenomics, which many hope
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human difference (and the processes of impersonal calculation of allelic frequency
distributions that sustain it) will perhaps irrationally exacerbate social notions of difference
and the inequalities that these have traditionally borne. Despite their good intentions,
many scientists in the field of pharmacogenetics believe, and therefore communicate, that
genetic difference sorts by race and, thus, that ‘there is a genetic basis for race or
ethnicity’. It thus follows that the rationalization of medicine is also proving to be a
rationalization of race in the name of better potential health care. As such, it runs the risk
of irrationalizing both.
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